Citadel Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-315,477
| Closed | -$4.72M | – | 16249 |
|
|
2022
Q4 | $4.72M | Buy |
315,477
+274,675
| +673% | +$3.8M | ﹤0.01% | 3951 |
|
|
2022
Q3 | $336K | Buy |
+40,802
| New | +$313K | ﹤0.01% | 9326 |
|
|
2022
Q1 | – | Sell |
-112,347
| Closed | -$463K | – | 15313 |
|
|
2021
Q4 | $527K | Buy |
112,347
+64,492
| +135% | +$400K | ﹤0.01% | 9578 |
|
|
2021
Q3 | $295K | Buy |
+47,855
| New | +$286K | ﹤0.01% | 11096 |
|
|
2021
Q2 | – | Sell |
-31,969
| Closed | -$220K | – | 15011 |
|
|
2021
Q1 | $234K | Sell |
31,969
-193
| -0.6% | -$1.67K | ﹤0.01% | 11405 |
|
|
2020
Q4 | $186K | Sell |
32,162
-6,764
| -17% | -$38.7K | ﹤0.01% | 9796 |
|
|
2020
Q3 | $231K | Sell |
38,926
-361,077
| -90% | -$1.79M | ﹤0.01% | 8589 |
|
|
2020
Q2 | $2.06M | Buy |
400,003
+383,720
| +2,357% | +$2.42M | ﹤0.01% | 4528 |
|
|
2020
Q1 | $59K | Buy |
16,283
+1,414
| +10% | +$7.02K | ﹤0.01% | 8957 |
|
|
2019
Q4 | $93K | Buy |
14,869
+9,622
| +183% | +$70.8K | ﹤0.01% | 8573 |
|
|
2019
Q3 | $44K | Buy |
+5,247
| New | +$39K | ﹤0.01% | 8743 |
|
|
2019
Q2 | – | Sell |
-20,309
| Closed | -$174K | – | 10225 |
|
|
2019
Q1 | $167K | Buy |
20,309
+4,161
| +26% | +$43K | ﹤0.01% | 8327 |
|
|
2018
Q4 | $258K | Sell |
16,148
-29,903
| -65% | -$658K | ﹤0.01% | 7502 |
|
|
2018
Q3 | $1.52M | Buy |
46,051
+41,561
| +926% | +$1.07M | ﹤0.01% | 4848 |
|
|
2018
Q2 | $101K | Buy |
+4,490
| New | +$106K | ﹤0.01% | 8236 |
|
|
2018
Q1 | – | Sell |
-84,382
| Closed | -$2.47M | – | 9050 |
|
|
2017
Q4 | $2.35M | Buy |
+84,382
| New | +$2.62M | ﹤0.01% | 3407 |
|
|
2017
Q3 | – | Sell |
-3,872
| Closed | -$120K | – | 8322 |
|
|
2017
Q2 | $86K | Buy |
3,872
+2,774
| +253% | +$21.8K | ﹤0.01% | 6959 |
|
|
2017
Q1 | $6K | Buy |
+1,098
| New | +$7.93K | ﹤0.01% | 7351 |
|
|
2016
Q4 | – | Sell |
-4,329
| Closed | -$28.9K | – | 8136 |
|
|
2016
Q3 | $39K | Buy |
+4,329
| New | +$40.8K | ﹤0.01% | 6906 |
|
|
2016
Q2 | – | Sell |
-2,746
| Closed | -$26.5K | – | 7685 |
|
|
2016
Q1 | $25K | Buy |
2,746
+1,043
| +61% | +$10.3K | ﹤0.01% | 6418 |
|
|
2015
Q4 | $21K | Buy |
1,703
+723
| +74% | +$8.6K | ﹤0.01% | 7905 |
|
|
2015
Q3 | $12K | Sell |
980
-2,924
| -75% | -$42.3K | ﹤0.01% | 8414 |
|
|
2015
Q2 | $67K | Buy |
+3,904
| New | +$70.3K | ﹤0.01% | 7451 |
|
|
2014
Q4 | – | Sell |
-372
| Closed | -$4K | – | 8852 |
|
|
2014
Q3 | $4K | Buy |
+372
| New | +$4.73K | ﹤0.01% | 7955 |
|
|
2013
Q3 | – | Sell |
-1,360
| Closed | -$34K | – | 6947 |
|
|
2013
Q2 | $34K | Buy |
+1,360
| New | +$58.1K | ﹤0.01% | 5851 |
|
Citadel Advisors's AVEO Position: Q1 2023 in Review
Citadel Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 315,477 shares — an estimated $4.72M sold.
Citadel Advisors first reported a position in AVEO in Q2 2013 and held it in 25 quarters. The position peaked at $4.72M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Citadel Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 315,477 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $4.72M.
- Citadel Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2013 and held it in 25 quarters.
- Citadel Advisors's AVEO Pharmaceuticals, Inc. position peaked at $4.72M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.